GH Research (NASDAQ:GHRS) Shares Up 1.2% – Time to Buy?

GH Research PLC (NASDAQ:GHRS)’s share price rose 1.2% on Tuesday . The company traded as high as $9.59 and last traded at $9.58. Approximately 2,276 shares traded hands during trading, a decline of 97% from the average daily volume of 79,618 shares. The stock had previously closed at $9.47.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on GHRS shares. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of GH Research in a research report on Thursday, September 5th. JMP Securities reaffirmed a “market outperform” rating and issued a $39.00 price target on shares of GH Research in a research note on Wednesday, September 4th. Finally, Canaccord Genuity Group cut their price objective on shares of GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a report on Monday.

GH Research Stock Down 0.4 %

The company has a market cap of $490.64 million, a price-to-earnings ratio of -12.13 and a beta of 0.74. The firm has a 50-day simple moving average of $7.78 and a 200 day simple moving average of $10.34.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings results on Tuesday, September 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.03. As a group, research analysts expect that GH Research PLC will post -0.85 EPS for the current year.

Institutional Trading of GH Research

An institutional investor recently raised its position in GH Research stock. RA Capital Management L.P. increased its stake in GH Research PLC (NASDAQ:GHRS) by 1.3% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,686,689 shares of the company’s stock after acquiring an additional 85,000 shares during the period. RA Capital Management L.P. owned approximately 12.85% of GH Research worth $44,734,000 as of its most recent SEC filing. 56.90% of the stock is owned by hedge funds and other institutional investors.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).